TABLE 1.
Median fluconazole and voriconazole MICs at 48 h for 79 unique C. glabrata strains from 14 patients receiving radiation for head and neck tumors
| Patient | No. of isolates | No. of unique isolatesa | Median MIC (μg/ml) at 48 hb
|
FLU resistancec | VORI susceptibilityd | |
|---|---|---|---|---|---|---|
| FLU | VORI | |||||
| 10 | 5 | 1 | 32 | 1 | DD-S | |
| 12 | 10 | 4 | 4 | 0.125 | S | |
| 8 | 0.125 | S | ||||
| 4 | 0.125 | S | ||||
| 4 | 0.125 | S | ||||
| 13 | 1 | 1 | 32 | 2 | DD-S | NS |
| 14 | 2 | 1 | 16 | 1 | DD-S | |
| 15 | 3 | 1 | 16 | 0.25 | DD-S | |
| 18 | 43 | 23 | 4 | 0.015 | S | |
| 4 | 0.015 | S | ||||
| 16 | 1 | DD-S | ||||
| 16 | 0.25 | DD-S | ||||
| 8 | 0.25 | S | ||||
| 8 | 0.5 | S | ||||
| 8 | 0.125 | S | ||||
| 4 | 0.125 | S | ||||
| 8 | 0.125 | S | ||||
| 4 | 0.125 | S | ||||
| 8 | 0.25 | S | ||||
| 8 | 0.5 | S | ||||
| 8 | 0.25 | S | ||||
| 8 | 0.25 | S | ||||
| 4 | 0.53 | S | ||||
| 4 | 1 | S | ||||
| 32 | 0.5 | DD-S | ||||
| 4 | 0.5 | S | ||||
| 8 | 1 | S | ||||
| 4 | 0.5 | S | ||||
| 4 | 0.25 | S | ||||
| >64 | 4 | R | NS | |||
| 64 | 2 | R | NS | |||
| 20 | 27 | 14 | 16 | 0.5 | DD-S | |
| 8 | 0.25 | S | ||||
| 32 | 0.5 | DD-S | ||||
| 16 | 1 | DD-S | ||||
| 16 | 2 | DD-S | NS | |||
| 16 | 0.5 | DD-S | ||||
| 32 | 2 | DD-S | NS | |||
| 32 | 1 | DD-S | ||||
| 4 | 0.25 | S | ||||
| <64 | 4 | R | NS | |||
| 8 | 0.25 | S | ||||
| 8 | 0.125 | S | ||||
| 16 | 0.25 | DD-S | ||||
| 4 | 0.03 | S | ||||
| 21 | 26 | 16 | 16 | 0.5 | DD-S | |
| 16 | 0.25 | DD-S | ||||
| 8 | 0.125 | S | ||||
| 16 | 1 | DD-S | ||||
| 16 | 0.5 | DD-S | ||||
| 8 | 0.5 | S | ||||
| 8 | 0.125 | S | ||||
| 32 | 0.5 | DD-S | ||||
| 32 | 1 | DD-S | ||||
| 32 | 0.5 | DD-S | ||||
| 16 | 0.5 | DD-S | ||||
| 8 | 0.5 | S | ||||
| 16 | 0.5 | DD-S | ||||
| 8 | 1 | S | ||||
| 8 | 0.5 | S | ||||
| 8 | 0.5 | S | ||||
| 22 | 3 | 2 | 8 | 0.5 | S | |
| 32 | 1 | DD-S | ||||
| 23 | 3 | 1 | 4 | 0.125 | S | |
| 25 | 26 | 11 | 8 | 0.06 | S | |
| 8 | 0.5 | S | ||||
| 8 | 0.5 | S | ||||
| 8 | 0.125 | S | ||||
| 8 | 0.5 | S | ||||
| 8 | 0.25 | S | ||||
| 4 | 0.25 | S | ||||
| 8 | 0.25 | S | ||||
| 8 | 1 | S | ||||
| 8 | 0.06 | S | ||||
| 32 | 0.03 | DD-S | ||||
| 27 | 4 | 2 | 16 | 1 | DD-S | |
| 8 | 1 | S | ||||
| 30 | 3 | 1 | 0.125 | 0.015 | S | |
| 31 | 5 | 1 | 32 | 2 | DD-S | NS |
a
Isolates were considered unique if they were from different patients or were from samples taken at different times from the same patient or if different karotypes of isolates from the same patient were displayed based on DNA karyotyping.
b
Data are given for each unique isolate. FLU, fluconazole; VORI, voriconazole.
c
S, isolate was susceptible; DD-S, isolate showed dose-dependent susceptibility; R, isolate was resistant. Designations are based on breakpoints discussed in the text.
d
NS, isolates for which the MICs are over the proposed voriconazole susceptibility breakpoint of ≤1 μg/ml (14).